Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Moriniere

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Endocrinology and Metabolism|September 1, 1991
Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patientsM E Solal, J L Sebert, B Boudailliez, et al.
Kidney International. Supplement|March 1, 1988
1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking Al(OH)3R Demontis, P F Westeel, B Boudalliez, et al.
Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress|January 1, 1985
1 alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH)3A Fournier, R Demontis, Y Tahiri, et al.
Clinical Nephrology|September 1, 1986
1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH)3R Demontis, A Leflon, A Fournier, et al.
Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress|January 1, 1985
Influence of biochemical and hormonal factors on the bone histomorphometric features of uraemic patientsA Fournier, J L Sebert, P Fohrer, et al.
Kidney International. Supplement|February 1, 1986
Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremiaA Fournier, P Moriniere, J L Sebert, et al.
Advances in Experimental Medicine and Biology|January 1, 1982
Effects of oral cimetidine on parathyroid hormone and calcitonin plasma levels in uremic patientsJ L Sebert, P H Decourcelles, P Moriniere, et al.
Kidney International. Supplement|June 1, 1993
Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calciumP Moriniere, N el Esper, B Viron, et al.
Artificial Organs|July 31, 1998
Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysisA Sechet, P Hardy, C Hottelart, et al.
Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress|January 1, 1985
The desferrioxamine test predicts bone aluminium burden induced by A1(OH)3 in uraemic patients but not mild histological osteomalaciaA Fournier, P Fohrer, P Leflon, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Endocrinology and Metabolism|September 1, 1991
Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patientsM E Solal, J L Sebert, B Boudailliez, et al.
Kidney International. Supplement|March 1, 1988
1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking Al(OH)3R Demontis, P F Westeel, B Boudalliez, et al.
Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress|January 1, 1985
1 alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH)3A Fournier, R Demontis, Y Tahiri, et al.
Clinical Nephrology|September 1, 1986
1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH)3R Demontis, A Leflon, A Fournier, et al.
Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress|January 1, 1985
Influence of biochemical and hormonal factors on the bone histomorphometric features of uraemic patientsA Fournier, J L Sebert, P Fohrer, et al.
Kidney International. Supplement|February 1, 1986
Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremiaA Fournier, P Moriniere, J L Sebert, et al.
Advances in Experimental Medicine and Biology|January 1, 1982
Effects of oral cimetidine on parathyroid hormone and calcitonin plasma levels in uremic patientsJ L Sebert, P H Decourcelles, P Moriniere, et al.
Kidney International. Supplement|June 1, 1993
Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calciumP Moriniere, N el Esper, B Viron, et al.
Artificial Organs|July 31, 1998
Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysisA Sechet, P Hardy, C Hottelart, et al.
Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress|January 1, 1985
The desferrioxamine test predicts bone aluminium burden induced by A1(OH)3 in uraemic patients but not mild histological osteomalaciaA Fournier, P Fohrer, P Leflon, et al.
Pageof 4